about
Differential expression of microRNAs in tumors from chronically inflamed or genetic (APC(Min/+)) models of colon cancerA minicircuitry involving REST and CREB controls miR-9-2 expression during human neuronal differentiationMicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3' untranslated regionCirculating microRNAs, potential biomarkers for drug-induced liver injuryMicroRNAs: Novel immunotherapeutic targets in colorectal carcinomaSmall Non-coding Transfer RNA-Derived RNA Fragments (tRFs): Their Biogenesis, Function and Implication in Human DiseasesMicromanaging abdominal aortic aneurysmsMicroRNA modulators of epigenetic regulation, the tumor microenvironment and the immune system in lung cancerMCP-1-induced protein-1, an immune regulatorRegulation of microRNA biogenesis and turnover by animals and their virusesEmerging role of microRNAs in liver diseasesMicroRNA-222 promotes tumorigenesis via targeting DKK2 and activating the Wnt/β-catenin signaling pathwayTargeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cellsMiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma CellsMultiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastomamicroRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma.MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabThe miR-99 family regulates the DNA damage response through its target SNF2HmiR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation.p53 and microRNA-34 are suppressors of canonical Wnt signaling.microRNA-34a is tumor suppressive in brain tumors and glioma stem cells.The role of microRNAs in glioma initiation and progression.MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A.A novel class of small RNAs: tRNA-derived RNA fragments (tRFs).Tumor suppressor function of miR-483-3p on squamous cell carcinomas due to its pro-apoptotic properties.PROGmiR: a tool for identifying prognostic miRNA biomarkers in multiple cancers using publicly available data.Mucins: a new family of epigenetic biomarkers in epithelial cancers.Detection of cancer with serum miRNAs on an oligonucleotide microarray.MicroRNAs: tools for cancer diagnosticsmicroRNA expression patterns reveal differential expression of target genes with age.UFFizi: a generic platform for ranking informative features.miR-539 inhibits FSCN1 expression and suppresses hepatocellular carcinoma migration and invasion.Evaluation of microRNA-205 expression as a potential triage marker for patients with low-grade squamous intraepithelial lesionsNovel primate-specific genes, RMEL 1, 2 and 3, with highly restricted expression in melanoma, assessed by new data mining toolThe microRNA and messengerRNA profile of the RNA-induced silencing complex in human primary astrocyte and astrocytoma cellsmicroRNA-664 enhances proliferation, migration and invasion of lung cancer cellsA Bayesian approach for identifying miRNA targets by combining sequence prediction and gene expression profiling.Investigation gene and microRNA expression in glioblastoma.PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.
P2860
Q21135494-9B34C8EC-2CA6-471C-AC74-36C4C100FE60Q24608565-BA6408B4-4985-457C-B569-900F0CD6DAB1Q24635277-957817A7-4A84-4CBE-9BD4-C08C8AC18A1EQ24656209-37A5A4DE-3250-4CA0-8FCB-C7432BA5B327Q26747339-BD658888-908B-4E86-8917-8DF4BD1A8A40Q26766672-B88CD0C4-A228-48DE-B820-F676A99A4CEAQ26823361-628392EF-F13D-43AF-BD01-7FAA6D2B3995Q26849525-14455AF7-EA3C-4345-AF18-CDC3021872DFQ26993217-7DB82241-988F-4570-8297-512505113CC9Q27014955-E3E3FD0D-5B40-4BDC-9FBB-BF29A05AC8BEQ27490492-1522DDBE-D6C5-4738-BDD7-EC705A1B1703Q28115534-99D45E60-5087-4A25-A469-F641B068BCF5Q28476781-94257C7D-7D05-4096-BFBB-DBCC080B2293Q28551027-037A6DFB-7BF5-48F3-9EFA-4C8FED8ECE73Q30405446-23E94B06-882C-4824-8707-A42BD7CB621EQ30407637-B7DE65D4-3380-4B07-A20C-DF3F4C4E6A59Q30414321-3E4EDA05-75EB-4E52-8A38-BC88166AF372Q30415894-2FBEEDEF-4D76-4EF5-87D8-7C667511C31CQ30417554-097C1A3E-B0A2-4375-9655-591B0AB4E2C9Q30423329-AD221B62-BE55-410A-BB09-FE6C6DC55B04Q30424916-4BDBE08F-88E0-4A21-9935-6C14555AAB4CQ30428366-64003609-3627-4693-B0E3-CE52273B7161Q30428370-31530BAF-F57E-48C3-AB0C-E0FFF198EEC2Q30434790-563E2916-2802-4C57-8958-6E1C7FB56F76Q30436133-EAF9170B-2F47-4851-91E8-6177F6F02D90Q30543779-DDAF70B0-1A9A-4B84-8FD0-72C2C79AC76BQ30583504-08E22707-1AFC-4060-A8F4-6A3282749722Q30597703-D2302D65-08A2-44E5-9541-AB1FFDDA5199Q33481633-0CB90C5F-E63F-4716-9D45-E17D0959CB02Q33575602-2038B510-20A0-4C90-9DFC-1AC9752C87DEQ33588546-D005EA35-C99E-4E67-815F-7331585AA7CEQ33594993-B7F29930-EFF3-42F4-A0F4-B425E93021F7Q33670786-B3AC38F9-5EB1-4886-9553-9FEA48DA4CC5Q33685531-7A5420CE-9CC7-4FC8-BE92-BF1DF55EF52EQ33728046-D30BE4E6-7183-4EC6-B2D9-A4BC34A3E32EQ33728363-153F0E3E-FBAD-455C-91C4-7AAC195BEE2AQ33745073-B83132FE-2D51-4D8C-B278-5313B26CF13DQ33766581-2F37B51A-778C-4B1F-9CF7-887F1AEA4019Q33766599-ADE2734A-FCA8-47D9-ADFE-832F32610FC5Q33767159-407B4AED-7F75-40FC-B512-B96C56A54834
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
MicroRNAs in cancer.
@ast
MicroRNAs in cancer.
@en
type
label
MicroRNAs in cancer.
@ast
MicroRNAs in cancer.
@en
prefLabel
MicroRNAs in cancer.
@ast
MicroRNAs in cancer.
@en
P2860
P1476
MicroRNAs in cancer.
@en
P2093
Yong Sun Lee
P2860
P304
P356
10.1146/ANNUREV.PATHOL.4.110807.092222
P577
2009-01-01T00:00:00Z